ST. JOSEPH, Mich., June 20 /PRNewswire/ -- GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that Boehringer Ingelheim has licensed its data mining suite, MetaCore, primarily for toxicogenomics research. MetaCore is based on a comprehensive, manually curated database of human biology, diseases, toxicology and bioactive chemistry.
"Toxicogenomics is one of the main applications of MetaCore, and we pay a lot of attention to the field in product development," said Julie Bryant, Vice President of Business Development at GeneGo. "We manually curate all major toxicity journals and develop tools and workflows specifically for the analysis of toxicogenomics datasets; the work is partly sponsored by an NIEHS grant. MetaCore was featured in many posters and presentations at the recent Society of Toxicology meeting in San Diego, and is applied by a growing number of toxicogenomics groups in industry and academia."
About GeneGo
GeneGo develops systems biology technology for life science research. The original computational platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, siRNA and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 3.2, assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore. For more information, please visit the company's web site at www.genego.com.
MetaCore(TM), MetaBase(TM) and MetaDrug(TM) are trademarks of GeneGo, Inc.
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 143 affiliates in 45 countries and about 37,500 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
In 2005, Boehringer Ingelheim posted net sales of 9.5 billion euro while spending approximately one fifth of net sales in its largest business segment Prescription Medicines on research and development.
For more information please visit www.boehringer-ingelheim.com
GeneGo, Inc.CONTACT: Julie Bryant, VP Business Development and Marketing of GeneGo,Inc., +1-858-756-7996, julie@genego.com
